16.09.2015 Views

Clinical Pharmacology and Therapeutics

A Textbook of Clinical Pharmacology and ... - clinicalevidence

A Textbook of Clinical Pharmacology and ... - clinicalevidence

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

170 ANTI-INFLAMMATORY DRUGS AND THE TREATMENT OF ARTHRITIS<br />

inflammatory process in inflammatory arthritis. Their mechanisms<br />

are generally poorly understood. They are used in<br />

patients with progressive disease. Response (though unpredictable)<br />

is usually maximal in four to ten weeks. Unlike<br />

NSAIDs, DMARDs reduce inflammatory markers (historically,<br />

it was this effect that led to them being referred to as ‘diseasemodifying’).<br />

It is difficult to prove that a drug influences the<br />

natural history of a relapsing/remitting <strong>and</strong> unpredictably progressing<br />

disease, such as rheumatoid arthritis, but immunosuppressants<br />

retard the radiological progression of bony<br />

erosions. DMARDs are toxic, necessitating careful patient monitoring,<br />

<strong>and</strong> are best used by physicians experienced in rheumatology.<br />

Rheumatologists use them earlier than in the past, with<br />

close monitoring for toxicity, with the patient fully informed<br />

about toxic, as well as desired, effects. This is especially important<br />

since many of these drugs are licensed for quite different<br />

indications to arthritis. In terms of efficacy, methotrexate, gold,<br />

D-penicillamine, azathioprine <strong>and</strong> sulfasalazine are similar,<br />

<strong>and</strong> are all more potent than hydroxychloroquine. Methotrexate<br />

(Chapter 48) is better tolerated than the other DMARDs, <strong>and</strong> is<br />

usually the first choice. Sulfasalazine (Chapter 34) is the second<br />

choice. Alternative DMARDs, <strong>and</strong> some of their adverse effects,<br />

are summarized in Table 26.1.<br />

GOLD SALTS<br />

Use<br />

Gold was originally introduced to treat tuberculosis. Although<br />

ineffective, it was found to have antirheumatic properties <strong>and</strong><br />

has been used to treat patients with rheumatoid arthritis since<br />

the 1920s. Sodium aurothiomalate is administered weekly by<br />

deep intramuscular injection. About 75% of patients improve,<br />

with a reduction in joint swelling, disappearance of rheumatoid<br />

nodules <strong>and</strong> a fall in C-reactive protein (CRP) levels. Urine<br />

must be tested for protein <strong>and</strong> full blood count (with platelet<br />

count <strong>and</strong> differential white cell count) performed before each<br />

injection. Auranofin is an oral gold preparation with less toxicity,<br />

but less efficacy than aurothiomalate. Treatment should<br />

be stopped if there is no response within six months.<br />

Mechanism of action<br />

The precise mechanism of gold salts is unknown. Several<br />

effects could contribute. Gold–albumin complexes are phagocytosed<br />

by macrophages <strong>and</strong> polymorphonuclear leukocytes<br />

<strong>and</strong> concentrated in their lysosomes, where gold inhibits lysosomal<br />

enzymes that have been implicated in causing joint<br />

damage. Gold binds to sulphhydryl groups <strong>and</strong> inhibits<br />

sulphhydryl–disulphide interchange in immunoglobulin <strong>and</strong><br />

complement, which could influence immune processes.<br />

Adverse effects<br />

Adverse effects are common <strong>and</strong> severe:<br />

• Rashes are an indication to stop treatment, as they can<br />

progress to exfoliation.<br />

• Photosensitive eruptions <strong>and</strong> urticaria are often preceded<br />

by itching.<br />

• Glomerular injury can cause nephrotic syndrome.<br />

Treatment must be withheld if more than a trace of<br />

proteinuria is present, <strong>and</strong> should not be resumed until<br />

the urine is protein free.<br />

• Blood dyscrasias (e.g. neutropenia) can develop rapidly.<br />

Table 26.1: Disease-modifying antirheumatic drugs (DMARDs)<br />

Drug Adverse effects Comments<br />

Immunosuppressants: Blood dyscrasias, carcinogenesis, Methotrexate is usually the first-choice<br />

azathioprine, methotrexate, opportunistic infection, alopecia, DMARD<br />

ciclosporin<br />

nausea; methotrexate also causes<br />

mucositis <strong>and</strong> cirrhosis; ciclosporin<br />

causes nephrotoxicity, hypertension<br />

<strong>and</strong> hyperkalaemia<br />

Sulfasalazine Blood dyscrasias, nausea, rashes, First introduced for arthritis, now used<br />

colours urine/tears orange<br />

mainly in inflammatory bowel disease<br />

(Chapter 34)<br />

Gold salts Rashes, nephrotic syndrome, Oral preparation (auranofin) more<br />

blood dyscrasias, stomatitis,<br />

convenient, less toxic, but less effective than<br />

diarrhoea<br />

intramuscular aurothiomalate<br />

Penicillamine<br />

Blood dyscrasias, proteinuria,<br />

urticaria<br />

Antimalarials: chloroquine, Retinopathy, nausea, diarrhoea, See Chapter 47<br />

hydroxychloroquine<br />

rashes, pigmentation of palate,<br />

bleaching of hair

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!